Director · LIGAND PHARMACEUTICALS INC · LIGAND PHARMACEUTICALS INC — Non-Qualified Stock Option (right to buy)
Side
M
Value
—
Shares
6,138
Price
—
Executed
Aug 12, 2026
Disclosed
Aug 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Aug 12 executedAug 14, 2026 disclosed
LGND · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
LIGAND PHARMACEUTICALS INC — Non-Qualified Stock Option (right to buy)
Ticker
LGND
Shares
6,138
Price per share
$0
Execution date (reported)
Aug 12, 2026
Owned after transaction
0 shares
Days from execution to publication
2
What this establishes
Haas Jason filed this Form 4 reporting a option exercise of LGND on Aug 12, 2026. It became public on Aug 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Haas Jasoncik:0001883821
Issuer
LIGAND PHARMACEUTICALS INCcik:0000886163
Revision history · 0
No field has changed since this record was first ingested.
